Schizophrenia

Table 1.

Effects of mGlu2/3 Receptor Agonists Relevant to Schizophrenia^a

Behavior^b	Neurochemistry^c	Electrophysiology^d
^a See (24, 33).
^b Results in traditional psychosis models (conditioned avoidance response, and pre-pulse inhibition of startle) have been negative or not seen across agents.
^c Focus has been on pharmacology in striatum (nucleus accumbens), prefrontal cortex, and limbic cortex/thalamus.
^d Focus has been on hippocampus, prefrontal cortex, amygdala, thalamocortical pathways.
Decrease in NMDA antagonist induced behaviors (locomotion, cognitive impairment, attention)	Decrease in PCP-induced glutamate release	Decrease in glutamate-evoked EPSPs
Decrease in amphetamine-induced behaviors (locomotion, rearing)	Decrease in PCP-induced release of 5HT, dopamine, and norepinephrine	Decrease in electrically evoked EPSPs
Decrease in 5HT_2A agonist induced behaviors (head-shaking)	Prevention of PCP-induced neuronal vacuolization and necrosis	Decrease in 5HT_2A agonist evoked glutamate EPSPs